ModifiedPremera BluecrossPolicy 5.01.662

Antiemetic Medications

Customize your policy alerts

Sign up for Premera Bluecross Policy 5.01.662 alerts

Get alerted when Policy 5.01.662 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Pharmacy benefit policy that defines medical necessity criteria, limits, and documentation for specific antiemetic drugs used for cancer-related, motion-sickness, pregnancy-related, and other indicated nausea/vomiting conditions. Applies to providers managing pharmacy benefit requests for Premera BlueCross members.

Policy Summary

PayerPremera Bluecross

PolicyAntiemetic Medications

Policy CodePolicy 5.01.662

Change TypeMaterial updates: new policy consolidation, added products, revised step and quantity limits

Effective DateAug 1, 2026

Last ReviewJul 27, 2026

Next Review DateJul 27, 2026

Key ActionObtain prior authorization through the pharmacy benefit and document prior trial and inadequate response or intolerance to required OTC or generic alternatives where step therapy is specified.

SourceLink

POLICY UPDATE CHANGES

New policy created and approved March 10, 2026; prescription drug section added and coverage criteria for several antiemetic agents moved from policy 5.01.605 into this policy.

Added new policy criteria for Nereus (tradipitant) for treatment of vomiting induced by motion sickness.

Updated Bonjesta and Diclegis criteria to require prior trial and inadequate response or intolerance to OTC pyridoxine plus OTC doxylamine.

Added quantity limits: Bonjesta 60 tablets/30 days; Diclegis and generic delayed-release 120 tablets/30 days; Varubi limited to 2 tablets per fill.

Updated Akynzeo criteria and set quantity to 1 capsule per fill; updated Sancuso criteria with quantity limit of 1 transdermal system per fill.

Added brand dronabinol solution to the policy with the same criteria as Syndros (dronabinol oral solution).

Updated Nereus (tradipitant) quantity limit from 30 capsules/15 days to 16 capsules/30 days.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedPremera BluecrossPolicy 5.01.662

Antiemetic Medications

Customize your policy alerts

Sign up for Premera Bluecross Policy 5.01.662 alerts

Get alerted when Policy 5.01.662 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerPremera Bluecross

PolicyAntiemetic Medications

Policy CodePolicy 5.01.662

Change TypeMaterial updates: new policy consolidation, added products, revised step and quantity limits

Effective DateAug 1, 2026

Last ReviewJul 27, 2026

Next Review DateJul 27, 2026

SourceLink

POLICY UPDATE CHANGES

New policy created and approved March 10, 2026; prescription drug section added and coverage criteria for several antiemetic agents moved from policy 5.01.605 into this policy.

Added new policy criteria for Nereus (tradipitant) for treatment of vomiting induced by motion sickness.

Updated Bonjesta and Diclegis criteria to require prior trial and inadequate response or intolerance to OTC pyridoxine plus OTC doxylamine.

Added quantity limits: Bonjesta 60 tablets/30 days; Diclegis and generic delayed-release 120 tablets/30 days; Varubi limited to 2 tablets per fill.

Updated Akynzeo criteria and set quantity to 1 capsule per fill; updated Sancuso criteria with quantity limit of 1 transdermal system per fill.

Added brand dronabinol solution to the policy with the same criteria as Syndros (dronabinol oral solution).

Updated Nereus (tradipitant) quantity limit from 30 capsules/15 days to 16 capsules/30 days.

Coverage Criteria for Antiemetic Medications

Cancer-related and other prescription antiemetics

Covered when ALL of the following are met for the specified drug:

Akynzeo (netupitant and palonosetron) - oral: The individual is aged 18 years or older AND has moderate-to-high emetic risk AND medication is being used in combination with dexamethasone and a serotonin receptor antagonist (e.g., ondansetron) AND the quantity is limited to 1 capsule per fill

From policy Cancer Related Antiemetics section

Emend (aprepitant) - oral (oncologic): The individual is aged 12 years or older AND has moderate-to-high emetic risk AND medication is being used in combination with dexamethasone and a serotonin receptor antagonist (e.g., ondansetron) AND has tried and had an inadequate response or intolerance to generic aprepitant AND the quantity is limited to either two 80 mg capsules per fill OR one TriPack (one 125-mg + two 80-mg) per fill

From policy Cancer Related Antiemetics section

Sancuso (granisetron transdermal system): The individual is aged 18 years or older AND has moderate-to-high emetic risk AND medication is being used in combination with a serotonin receptor antagonist (e.g., ondansetron) AND quantity limit as specified in the policy

From policy Cancer Related Antiemetics section; Sancuso age statements appear in source

Varubi (rolapitant): The individual is aged 18 years or older AND has moderate-to-high emetic risk AND medication is being used in combination with dexamethasone and a serotonin receptor antagonist (e.g., ondansetron) AND the quantity is limited to 2 tablets per fill

From policy Cancer Related Antiemetics section

Brand dronabinol solution / Syndros (dronabinol oral solution): The individual is aged 18 years or older AND requires treatment for either chemotherapy-associated nausea and vomiting with inadequate response to conventional antiemetics OR anorexia with weight loss in AIDS AND has tried and had an inadequate response or intolerance to generic dronabinol capsules OR documentation is provided that the solution is medically necessary (e.g., unable to swallow solid dosage form)

From policy Cancer Related Antiemetics section

Post-operative and motion-sickness related

Covered when ALL of the following are met for the specified indication:

Emend (aprepitant) - post-operative nausea and vomiting: The individual is aged 18 years or older AND has tried and had an inadequate response or intolerance to generic aprepitant AND the quantity is limited to either two 80 mg capsules per fill OR one TriPack (one 125-mg + two 80-mg) per fill

From policy Coverage Criteria (post-operative)

Nereus (tradipitant) - motion sickness: The individual is aged 18 years or older AND there is no evidence of another underlying condition causing chronic nausea AND has tried and had an inadequate response or intolerance to all listed comparator agents (e.g., first-generation antihistamines, scopolamine) AND the dose is limited to 170 mg daily AND the quantity is limited to 16 capsules per 30 days

From policy Motion Sickness Related Antiemetics section

Pregnancy-related antiemetics

Covered when ALL of the following are met for pregnancy-related nausea/vomiting:

Bonjesta (doxylamine and pyridoxine ER): The individual has tried and had an inadequate response or intolerance to over-the-counter pyridoxine in combination with over-the-counter doxylamine AND has tried and had an inadequate response or intolerance to generic doxylamine and pyridoxine delayed-release AND the quantity is limited to 60 tablets per 30 days

From Pregnancy Related Antiemetics section

Diclegis (doxylamine and pyridoxine DR) and generic doxylamine/pyridoxine DR: The individual has tried and had an inadequate response or intolerance to over-the-counter pyridoxine in combination with over-the-counter doxylamine; Diclegis quantity limited to 60 tablets per 30 days; generic delayed-release quantity limited to 120 tablets per 30 days

From Pregnancy Related Antiemetics section

Product-specific coverage criteria (summary)

Coverage for specific antiemetic drugs is subject to product-specific clinical criteria and quantity limits as detailed in this policy.

Doxylamine/pyridoxine (Bonjesta, Diclegis, generic DR): Coverage requires prior trial and inadequate response or intolerance to over-the-counter pyridoxine in combination with over-the-counter doxylamine; Bonjesta limited to 60 tablets per 30 days; Diclegis and generic delayed-release limited to 120 tablets per 30 days

From policy history and quantity limits updates

Akynzeo (netupitant and palonosetron): Criteria updated and quantity limited to 1 capsule per fill1 capsule per fill

From policy history updates

Sancuso (granisetron transdermal system): Criteria updated and quantity limited to 1 transdermal system per fill1 transdermal system per fill

All uses of the drugs described in this policy that are not listed among the specific covered indications (for example, cancer-related antiemesis, motion-sickness related vomiting, post-operative nausea/vomiting, or pregnancy-related nausea/vomiting where criteria are met) are considered investigational and may be denied. Documentation submitted must demonstrate that the request meets one of the policy’s defined medical necessity criteria; uses outside those indications do not meet coverage criteria per this policy.

This policy is a pharmacy benefit medical policy and does not apply to Medicare Advantage. Providers and members should consult the member benefit booklet or contact customer service to determine coverage under specific member plans.

Coding

Codingmixed

No codes listed

Provider Actions, Prior Authorization & Documentation

Prior Authorization

Pharmacy benefit management and approval duration

This policy is managed through the pharmacy benefit. Prior authorization may be required per pharmacy benefit processes and, when criteria are met, approvals may be granted for up to 12 months.

Prior Authorization

Prior authorization required; product-specific quantity limits

Prior authorization is required for covered prescription antiemetic products and approvals are subject to product-specific clinical criteria and defined quantity limits (per fill or per 30 days) as stated in the policy.

Akynzeo: quantity limited to 1 capsule per fill
Sancuso: quantity limited to 1 transdermal system per fill
Bonjesta: quantity limited to 60 tablets per 30 days
Diclegis and generic delayed-release: quantity limited to 120 tablets per 30 days
Varubi: quantity limited to 2 tablets per fill

Background

Nausea and vomiting are mediated by a central vomiting center that receives input from multiple pathways, including the chemoreceptor trigger zone, vestibular system, and gastrointestinal tract. Key receptor systems implicated include 5-HT3 (serotonin) and NK1 (neurokinin-1), among others; antiemetic drug classes target these receptors to prevent or treat symptoms. Combination regimens (for example, an NK1 receptor antagonist plus a 5-HT3 receptor antagonist and dexamethasone) are commonly used for moderate-to-high emetic risk clinical situations such as chemotherapy-induced nausea and vomiting.

Definitions and Regimen Guidance

Moderate-to-high emetic risk (oncologic treatment)

DefinitionClinical designation per oncology guidelines where combination antiemetic regimens (including NK1 RA, 5-HT3 RA, and dexamethasone, sometimes with olanzapine) are recommended for patients receiving oncologic treatment with moderate-to-high emetic risk.

Clinical implicationPatients with moderate-to-high emetic risk should receive combination antiemetic therapy (e.g., NK1 RA + 5-HT3 RA + dexamethasone) as part of prophylaxis for chemotherapy-associated nausea and vomiting.

Related drug classesNK1 receptor antagonists, 5-HT3 receptor antagonists, dexamethasone, olanzapine (when indicated).

Policy age referencesUsed in oncology coverage criteria for agents with age-specific thresholds (examples in policy include age ≥12 or ≥18 years depending on drug).

Preferred high-emetic-risk regimen

Initial Therapy Criteria

Initial therapy

Initial authorization criteria per drug:

Akynzeo initial: Age ≥18 AND moderate-to-high emetic risk AND used with dexamethasone and a 5-HT3 RA AND quantity limited to 1 capsule per fill

Chunk 3

Emend initial (oncologic): Age ≥12 AND moderate-to-high emetic risk AND used with dexamethasone and a 5-HT3 RA AND prior inadequate response or intolerance to generic aprepitant AND quantity limits as specified (two 80 mg capsules per fill OR one TriPack)

Chunk 3

Bonjesta/Diclegis initial (pregnancy): Trial and inadequate response or intolerance to OTC pyridoxine + OTC doxylamine required before prescription product; quantity limits apply (Bonjesta 60/30 days; Diclegis 60/30 days; generic DR 120/30 days)

Chunks 6 & 7

Continuation / Re-authorization Criteria

Continuation therapy

Re-authorization:

General re-authorization: Re-authorization of all drugs listed (unless noted otherwise) may be approved up to 12 months as long as drug-specific coverage criteria are met and chart notes show continued positive clinical response

From Length of Approval and Re-authorization criteria

Nereus (tradipitant) continuation

Nereus-specific continuation:

Nereus re-authorization: Initial approval is for 30 days; each additional treatment course is evaluated as an initial authorization and the individual must meet medical necessity criteria as listed in the motion sickness section

From Motion Sickness Related Antiemetics and History

Step Therapy Requirements

Step requirement	Examples / affected products	Required failure/try
Prior trial of listed alternatives is required before coverage of certain branded products
Emend (aprepitant) oral formulations; brand dronabinol solution / Syndros; Bonjesta (doxylamine/pyridoxine ER); Diclegis (doxylamine/pyridoxine DR); Akynzeo (netupitant and palonosetron); Varubi (rolapitant)
Documented trial and inadequate response or intolerance to specified generic or OTC alternatives (examples in policy: generic aprepitant prior to Emend; generic dronabinol capsules or documentation of medical necessity for solution; prior trial of listed comparator agents for Nereus).

Step requirement	Products affected	Required failure/try
Must try OTC pyridoxine in combination with OTC doxylamine prior to coverage
Bonjesta (doxylamine and pyridoxine extended‑release); Diclegis (doxylamine and pyridoxine delayed‑release); generic doxylamine/pyridoxine delayed‑release products
Documented trial and inadequate response or intolerance to over‑the‑counter pyridoxine combined with over‑the‑counter doxylamine is required before prescription product coverage; policy history and product criteria specify this prior OTC trial requirement.

Quantity Limits (per-fill / per-period)

Akynzeo (netupitant and palonosetron) — Quantity limit detail

ProductAkynzeo (netupitant and palonosetron)

Quantity limit1 capsule per fill

Policy noteQuantity updated and consolidated into policy 5.01.662 per history entries.

Emend (aprepitant) — two 80 mg capsules or one TriPack (one 125-mg + two 80-mg)

ProductEmend (aprepitant) - oral

Quantity optionsTwo 80 mg capsules per fill OR one TriPack per fill (one 125-mg + two 80-mg)

Age criterion

Site of Care

Note

Site of care: pharmacy benefit (home)

Managed through the pharmacy benefit.

Policy Summary

PayerPremera Bluecross

PolicyAntiemetic Medications

Policy CodePolicy 5.01.662

Change TypeMaterial updates: new policy consolidation, added products, revised step and quantity limits

Effective DateAug 1, 2026

Last ReviewJul 27, 2026

Next Review DateJul 27, 2026

SourceLink

On This Page

Varubi (rolapitant): Coverage criteria updated with quantity limited to 2 tablets per fill2 tablets per fill

From policy history updates

Nereus (tradipitant): Newly added indication: treatment of vomiting induced by motion sickness; quantity limit changed to 16 capsules per 30 days16 capsules per 30 days

From policy history updates

Dronabinol solution (brand added): Brand dronabinol solution added with the same criteria as Syndros (dronabinol oral solution)

From policy history updates

Step Therapy

Step/stepwise therapy expectations for branded agents

Certain branded agents require a prior trial and documented inadequate response or intolerance to the listed alternatives before the brand product will be covered.

Examples include prior trial requirements for branded aprepitant (Emend) and brand dronabinol products versus generic alternatives.

Step Therapy

Step therapy: OTC pyridoxine + OTC doxylamine trial required

Prior trial and documented inadequate response or intolerance to over‑the‑counter pyridoxine combined with over‑the‑counter doxylamine is required before coverage of prescription doxylamine/pyridoxine products.

This requirement applies to Bonjesta, Diclegis, and generic doxylamine/pyridoxine delayed‑release products.

Documentation Required

Required documentation: clinical records and medication history

Submit medical records (office visit notes) documenting the diagnosis, relevant history, physical evaluation and medication history to demonstrate that medical necessity criteria are met.

Records must show the diagnosis and clinical rationale for the requested antiemetic.
Include prior medication trials and outcomes where step requirements apply (e.g., OTC pyridoxine + doxylamine results).

Documentation Required

Required documentation for Bonjesta and Diclegis prior OTC trial

When Bonjesta or Diclegis is requested, documentation must specifically support a prior trial and inadequate response or intolerance to over‑the‑counter pyridoxine plus over‑the‑counter doxylamine; pharmacy claims must reflect applicable quantity limits.

Document the OTC trial and outcome in the chart notes.
Ensure dispensed quantity aligns with policy limits (Bonjesta 60/30 days; Diclegis/generic 120/30 days).

Denial Risk

Investigational uses may be denied

Requests for uses of these drugs for indications not listed in this policy are considered investigational and may be denied.

Do not submit requests for unlisted conditions without supporting evidence; such uses are outside this policy's covered indications.

Denial Risk

Common denial triggers (examples)

Denial may be triggered by failure to meet updated product‑specific criteria (for example, not documenting a prior OTC trial for doxylamine‑pyridoxine products) or by exceeding the policy's specified quantity limits.

Examples of denial triggers: missing documentation of required prior trials, requests exceeding per‑fill or per‑30‑day quantity caps (e.g., Bonjesta, Diclegis, Varubi, Nereus).

ContextRecommended as the preferred combination treatment for individuals undergoing oncologic treatment with high emetic risk per NCCN guidelines.

Moderate emetic risk regimen options

Option 15-HT3 RA + Dexamethasone

Option 2Olanzapine + Palonosetron + Dexamethasone

Option 3NK1 RA + 5-HT3 RA + Dexamethasone

ContextCombination options recommended by NCCN for individuals undergoing oncologic treatment with moderate emetic risk.

Varubi (rolapitant) — Quantity limit 2

ProductVarubi (rolapitant)

Quantity limit2 tablets per fill

Indication contextFor prevention of nausea and vomiting associated with oncologic treatment when used with dexamethasone and a 5-HT3 RA.

Bonjesta / Diclegis / generic doxylamine-pyridoxine DR — Quantity limits

ProductsBonjesta (doxylamine and pyridoxine ER) and Diclegis / generic doxylamine-pyridoxine DR

Quantity limitsBonjesta: 60 tablets per 30 days; Diclegis: 60 tablets per 30 days; Generic delayed-release: 120 tablets per 30 days

Step requirementCoverage requires prior trial and inadequate response or intolerance to OTC pyridoxine plus OTC doxylamine before prescription product coverage.

Nereus (tradipitant) — 16 capsules per 30 days (quantity limit)

ProductNereus (tradipitant)

Quantity limit16 capsules per 30 days

Indication and dosing noteAdded for treatment of vomiting induced by motion sickness; dose limited to 170 mg daily and initial approval for 30 days with re-evaluation for additional courses.

Akynzeo (netupitant and palonosetron) — quantity 1 per fill

ProductAkynzeo (netupitant and palonosetron)

Per-fill limitQuantity limited to 1 capsule per fill

Policy historyAkynzeo criteria updated and quantity set to 1 capsule per fill when consolidated into this policy.

Sancuso (granisetron transdermal system) — 1 per fill

ProductSancuso (granisetron transdermal system)

Per-fill limit1 transdermal system per fill

ContextSancuso criteria updated with a quantity limit when moved into policy 5.01.662.

Bonjesta (doxylamine and pyridoxine ER) — 60 tablets per 30 days

ProductBonjesta (doxylamine and pyridoxine ER)

Quantity limit60 tablets per 30 days

Coverage requirementRequires prior trial and inadequate response or intolerance to OTC pyridoxine plus OTC doxylamine and generic delayed-release prior to coverage.

Diclegis (doxylamine and pyridoxine DR) and generic DR — 120 tablets per 30 days

ProductsDiclegis (doxylamine and pyridoxine DR) and generic doxylamine/pyridoxine DR

Quantity limit120 tablets per 30 days (generic DR); Diclegis listed with 60 tablets per 30 days in parts of policy and history clarifies Diclegis quantity was updated—policy identifies Diclegis with 60 while generic DR is 120).

Step requirementPrior trial and inadequate response or intolerance to OTC pyridoxine + OTC doxylamine required before coverage.

Varubi (rolapitant) — 2 tablets per fill

ProductVarubi (rolapitant)

Per-fill quantity2 tablets per fill

Policy contextQuantity limit added when criteria were updated and consolidated into this policy.

Nereus (tradipitant) — 16 capsules per 30 days (repeated limit)

ProductNereus (tradipitant)

Quantity limit16 capsules per 30 days

History noteQuantity adjusted from prior limit (30 caps/15 days) to 16 caps/30 days per policy history.